Protagenic Therapeutics, Inc.\new financial data

Symbol
PTIX, PTIXW on OTC
Location
New York, NY
Fiscal year end
31 March
Latest financial report
09 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30% % -88%
Quick Ratio 0.01% %
Debt-to-equity -200% % -554%
Return On Assets -129% % 31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,810,208 shares -76%
Common Stock, Shares, Outstanding 1,934,878 shares 274%
Entity Public Float $4,042,876 USD -54%
Common Stock, Value, Issued $195 USD 275%
Weighted Average Number of Shares Outstanding, Basic 1,934,878 shares -64%
Weighted Average Number of Shares Outstanding, Diluted 1,934,878 shares -64%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $1,701,499 USD 4.3%
General and Administrative Expense $1,057,684 USD 183%
Operating Income (Loss) $5,831,487 USD -107%
Nonoperating Income (Expense) $675,232 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $5,156,255 USD -48%
Income Tax Expense (Benefit) $2,524 USD
Net Income (Loss) Attributable to Parent $5,156,255 USD -48%
Earnings Per Share, Basic -3.45 USD/shares 40%
Earnings Per Share, Diluted -3.45 USD/shares 40%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current $1,592,025 USD -79%
Inventory, Net $1,074 USD
Assets, Current $2,299,037 USD 22%
Property, Plant and Equipment, Net $38,836 USD -47%
Intangible Assets, Net (Excluding Goodwill) $2,093,228 USD
Assets $4,431,101 USD 127%
Accounts Payable, Current $2,030,191 USD
Accrued Liabilities, Current $252,947 USD
Liabilities, Current $6,823,789 USD 624%
Liabilities $6,823,789 USD 624%
Accumulated Other Comprehensive Income (Loss), Net of Tax $129,861 USD -50%
Retained Earnings (Accumulated Deficit) $9,113,856 USD 75%
Stockholders' Equity Attributable to Parent $2,392,688 USD 28%
Liabilities and Equity $4,431,101 USD 127%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,167,263 USD -374%
Net Cash Provided by (Used in) Financing Activities $4,422,960 USD 359%
Net Cash Provided by (Used in) Investing Activities $943,180 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 1,934,878 shares 274%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $965,509 USD -112%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,212,646 USD 2681%
Deferred Tax Assets, Valuation Allowance $8,713,000 USD 23%
Deferred Tax Assets, Gross $8,713,000 USD 23%
Depreciation $50,287 USD 100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,119,742 USD -43%
Property, Plant and Equipment, Gross $76,550 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2,000,000 shares -90%
Additional Paid in Capital $6,940,978 USD -81%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%